Navigation Links
University Hospitals Case Medical Center testing gene therapy for Alzheimer's disease
Date:1/7/2010

University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain. University Hospitals (UH) is the only site in the Midwest for the study. The study is sponsored by a contract to Case Western Reserve University from the Alzheimer's Disease Cooperative Study (ADCS) through a grant from the National Institute on Aging in association with Ceregene, Inc., which developed and will provide the active agent CERE-110.

NGF is a naturally occurring protein that may prevent nerve cells in the brain from dying and may help these cells function better. During the study, CERE-110 will be injected by a neurosurgeon into the nucleus basalis of Meynert, an area of the brain where nerve cells die in patients with AD.

"A small study in humans showed that CERE-110 was generally safe and well-tolerated," said Alan J. Lerner, M.D., principal investigator of the Cleveland site, director of the UH Neurological Institute Memory and Cognition Center, and a professor of neurology at the Case Western Reserve University School of Medicine.

The Phase 2 study will evaluate whether the therapy is safe for a larger group of patients and whether it helps the symptoms of AD. In total, 50 patients will be enrolled throughout the United States and UH aims to enroll at least five patients in this study.

"Should the clinical development of this therapy be successful, CERE-110 could offer the possibility of delaying the course of Alzheimer's disease, a real improvement over existing therapies," said Dr. Lerner. "This would not be a cure for AD, but a way of slowing it down."

Participants in the Phase 2 study will be randomly placed into one of two treatment groups, with half of the subjects receiving CERE-110 and the other half receiving placebo surgery. At the completion of the trial, subjects in the placebo arm may have the opportunity to receive the active treatment if the product seems safe and effective.


'/>"/>

Contact: George Stamatis
george.stamatis@UHhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. A study by the MUHC and McGill University opens a new door to understanding cancer
2. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
3. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
4. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
5. Binghamton University researchers investigate evolving malaria resistance
6. Antioxidant to retard wrinkles discovered by Hebrew University researcher
7. Society for General Microbiology 161st Meeting, University of Edinburgh
8. Boston University biomedical engineers find chink in bacterias armor
9. KAUST and American University in Cairo to collaborate on research and academic development
10. UNH becomes first university in nation to use landfill gas as primary energy source
11. University of Minnesota study refutes belief that black men have more aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/13/2017)... Germany , March 13, 2017 Future of security: ... ... DERMALOGs Face Matching enables to match face ... forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric ...
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum Review IRB ... in multiple sessions at this week’s Association of Clinical Research Professionals (ACRP) 2017 ... in clinical research. , "We are excited to present subject matter expertise on topics ...
(Date:4/24/2017)... NEW YORK , April 24, 2017  Dante Labs ... interpretation at only EUR 850 (ca. $900). While American individuals ... marks the first time Europeans can access WGS below EUR ... which are crucial to leveraging genetic information to make informed ... more. ...
(Date:4/21/2017)... ... , ... Having worked on the design of the innovative Triton™ lab ... top lab design architects from around the country at the Lab Design Conference 2017 ... Engineering Greg Casey will be at the show, where they will highlight the unique ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... and related applications were the focus of researchers, engineers, product developers, and industry ... in Anaheim. , Sponsored by SPIE, the international society for optics and ...
Breaking Biology Technology: